Nokihara H, Yano S, Sone S
Third Department of Internal Medicine, University of Tokushima School of Medicine.
Nihon Rinsho. 1997 May;55(5):1128-34.
P-glycoprotein is one of the key molecules in multidrug resistance. Monoclonal antibodies against P-glycoprotein could be useful tools for killing MDR tumor cells. To overcome multidrug resistance, many anti-P-glycoprotein monoclonal antibodies have been made such as MRK16 and MRK17. Conjugated moAb, such as bispecific antibody, immunotoxin and radioisotope conjugates have also been constructed to enhance the anti-tumor activity of moAb. Cytokine-gene transduction for accumulation and activation of monocytes may be hopeful to augment the therapeutic efficiency of anti-P-glycoprotein antibody. For clinical use, construction of human moAb, overcoming tumor heterogeneity, and protection of normal tissue by specifically targeting the tumor cells should be essential.
P-糖蛋白是多药耐药中的关键分子之一。抗P-糖蛋白单克隆抗体可能是杀死多药耐药肿瘤细胞的有用工具。为克服多药耐药性，已制备了许多抗P-糖蛋白单克隆抗体，如MRK16和MRK17。还构建了结合型单克隆抗体，如双特异性抗体、免疫毒素和放射性同位素结合物，以增强单克隆抗体的抗肿瘤活性。通过细胞因子基因转导来积累和激活单核细胞可能有望提高抗P-糖蛋白抗体的治疗效果。对于临床应用，构建人源单克隆抗体、克服肿瘤异质性以及通过特异性靶向肿瘤细胞来保护正常组织至关重要。
